Number of patients screened	33
Number of patients enrolled	24
Number of patients evaluable for toxicity	24
Number of patients evaluated for efficacy	24
Evaluation method	RECIST 1.1
Response assessment, CR	0(0%)
Response assessment, PR	20.8%
Response assessment, SD	2(8.3%)
Response assessment, PD	14(58.3%)
Response assessment, Other	3(16.7%)
(Median) Duration assessments, PFS	2.1 months; CI 2.1-4.3
(Median) Duration assessments, OS	12.7 months; CI 5.8-NA
(Median) Duration assessments, Response duration	2.8 months
Duration of treatment

Three patients were not assessed (PD [n = 2) and death [n = 1)]. Phase Ia enrolled 2 patients with NET evaluated as one SD and one PD, and one NEC evaluated as PR.